Paul Mampilly Urges Investors To Visualize The Future Before Investing

Paul Mampilly is the go-to person in matters investments and money markets. He is the founder of Profits Unlimited, a newsletter that provides professional guidance to Americans who are willing to invest in the American stock market. The newsletter informs Americans on when to invest and when to divest from the stock market among other invaluable advice.

Mampilly’s newsletters have gained popularity with many Americans. Perhaps, because of his vast experience acquired from Wall Street and other professional positions, but one thing stands out about Mampilly: he is a hands-on person, he has an impressive investment record. Mampilly’s investments at Netflix and Sarepta Therapeutics yielded notable returns. In 2008 when he invested in Netflix, the company share prices rose substantially enabling him to recoup his investment with a profit to boot. In 2012, Mampilly acquired shares at Sarepta which he later sold for 2000% profit.

Paul Mampilly often gets asked the question, ‘’what should I invest in?’’ He has three answers: electric vehicles, precision medicine, and food delivery systems. He supports his investment options with detailed explanations.

Read more on stockgumshoe.com

Mampilly observes the dining habits of millennials, and he believes that investors are out to make a killing from these eating preferences. Millennials prefer to have their food delivered to their homes. Food delivery companies are on the rise, and Mampilly urges investors to buy stocks from food distribution companies.

Some car manufacturers such as Tesla Motors are on the verge of revolutionizing land transport with the introduction of electric vehicles. Mampilly argues that gasoline powered cars will be eliminated soon. He urges investors to put their money in companies that are offering alternatives to gas powered vehicles.

Precision medicine aims to personalize the treatment provided to patients. It involves personalization of healthcare with medical decisions, practices, and products that are targeted to the individual patient. Mampilly believes that technology is hastening the pace at which we are approaching precision medicine and forward thinking people should consider this field.

Mampilly is an American investor with interests in finance, investment, and Wall Street. He worked at Banker’s Trust, Royal Bank of Scotland, ING, and Deutsche Bank before retiring to concentrate on his family and his interests which involves helping Americans make wise investment decisions.

Find more about Paul Mampilly: http://creditorweekly.com/index.php/2017/07/25/investor-paul-mampilly-and-his-wall-street-expertise/

Leave a Reply

Your email address will not be published. Required fields are marked *